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In a recent article, Wang and colleagues reported the
discovery of a mechanism by which CARM1 regulates
the genomic localization of BAF155 (a SWI/SNF
subunit involved in chromatin remodeling) through
post-translational methylation at R1064 arginine
residues. This modification leads to the relocalization
of BAF155-containing SWI/SNF complexes to regions
containing genes involved in the Myc oncogenic
pathway. The results presented are evidence that
these interactions constitute a mechanism by which
the BAF155 chromatin remodeling factor contributes
to cancer.pared with the advantages of recently developed genome
editing techniques for studying the biological activitiesBackground
A consistent finding across various cancer genome
sequencing projects is the identification of recurrent
mutations in genes known to be functionally involved in
processing histone marks or controlling chromatin
dynamics. These mutations are collectively referred to
as epigenetic genes. As an example, recurrent mutations
in breast cancer are found in chromatin remodeling fac-
tors such as ARID1A, ARID1B and SMARCD1 [1-4].
These observations reinforce the link between deregulated
chromatin remodeling processes and cancer development,
as research indicated as far back as the late 1990s [5].
But how? What is the mechanism? Mechanistic insight
has been lacking and there is very little direct informa-
tion to show how deregulated chromatin remodeling,
whether through acquired mutations in genes encoding* Correspondence: mesteller@idibell.cat
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Wang and colleagues recently carried out elaborate
experiments that enabled them to identify BAF155
(a subunit of the SWI/SNF complex) as a substrate for
CARM1 methyltransferase and to provide insight into
the mechanism by which this factor can lead to or
enhance the process of cancer origin development and
progression [7].CARM1-mediated methylation of BAF155 at
arginine residue R1064
The results presented by Wang and colleagues bring into
sharp focus the limitations of RNA interference com-
of enzymes in vivo. Using an experimental system for
monitoring the dynamics of arginine methylation, and
through short hairpin RNA-mediated knockdown of
CARM1 mRNA transcripts (90% reduction) in MCF7
breast cancer cell lines, the authors demonstrate that the
RNA interference technique is insufficient to reduce
CARM1 methyltransferase functionality. Even very lim-
ited expression levels of CARM1 were shown to be suffi-
cient to sustain its methyltransferase activity. Using the
zinc finger nuclease technique, CARM1 knockout clones
were generated for the MCF7 and MDA-MB-231 breast
cancer models and the HEK293T kidney cell line and
were validated as CARM1 dysfunctional.
By carrying out immunoprecipitation and mass spec-
trometry, Wang and colleagues identified BAF155 (also
known as SMARCC1) as a substrate of CARM1 methyl-
transferase activity [7]. The authors then demonstrated
that methylation of BAF155 at arginine residue R1064
affects the colony-formation capacity of MCF7 breast
cancer cells and that this modification is entirely
dependent on CARM1. Chromatin immunoprecipitation
and high-throughput DNA sequencing of BAF155 further
showed that BAF155 arginine methylation dramaticallyed Central Ltd. The licensee has exclusive rights to distribute this article, in any
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be enriched at genes involved in the c-Myc pathway – well
known for its link to carcinogenesis – and to be a poten-
tial marker for clinical applications in cancer diagnosis
and prognosis.
The clinical value of deregulated chromatin
remodeling factors in cancer: a novel therapeutic
approach?
In the past few years the field of cancer epigenetics has
attracted considerable attention because of its potential
in the area of personalized medicine [8]. The results of
Wang and colleagues contribute to this purpose by sug-
gesting a potential therapeutic approach for targeting
the regulators of chromatin remodeling factors; that is,
CARM1 methyltransferase inhibition by small-molecule
drug compounds. This would be predicted to inhibit
relocalization of BAF155 and thereby abolish its ability
to promote the expression of Myc-pathway oncogenes.
This therapeutic option could be useful in the context of
lowering the risk of disease relapse or, equally relevant,
as a cancer-preventative strategy in high-risk groups (for
example, in BRCA1 or BRCA2 mutation carriers). RNA
interference knockdown experiments revealed CARM1
be a difficult target, however, so it might be impossible
to inhibit the methyltransferase effectively at clinically
achievable doses. Nevertheless, it is intriguing that, by
targeting post-translational modifiers of chromatin re-
modeling factors, we could influence whether they occupy
genes that confer either oncogenic or tumor-suppressive
properties.
Several cancer-associated chromatin remodeling factors
other than BAF155 have already been identified in breast
cancer; for example, ARID1A, ARID1B, SMARCD1,
PBRM1, BAF60A and BRG1. Exciting new evidence is
emerging from the discovery that ARID1A-mutant cancer
cells are highly vulnerable to loss of ARID1B expression
[9], and similarly for BRG1/SMARCA4-mutated cancers
to the loss of BRM/SMARCA2 [10]. Another notable
example in this context includes the development of
LSD1 drug inhibitors, since this gene is part of the NuRD-
chromatin remodeling complex [11].
In conclusion, the discoveries made by Wang and
colleagues are an important source of insight as they not
only provide a mechanistic explanation of how deregulated
chromatin remodeling factors can contribute to cancer,
but also hint at therapeutic potentials that deserve further
attention in preclinical research.
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